Option Care Health (OPCH) opened 2026 with Q1 revenue of US$1.4b and basic EPS of US$0.29, setting the tone for how the year is starting to shape up after a busy 2025. The company has seen quarterly revenue move from US$1.33b in Q1 2025 to US$1.35b in Q1 2026, while basic EPS shifted from US$0.28 to US$0.29 over the same period, giving you a clean view of how the top and bottom lines are tracking across the year on year comp. With trailing margins softer than a year ago, this latest print puts profitability in the spotlight and makes the quality of those margins the key lens for reading the quarter.

See our full analysis for Option Care Health.

With the headline numbers on the table, the next step is to see how they compare with the widely followed narratives around growth, profitability and risk that have built up around Option Care Health in recent years.

Margins Under Pressure With 3.6% Net Profit

• On a trailing basis, net profit margin sits at 3.6%, compared with 4.1% a year earlier, and trailing net income of US$206.2 million on US$5.7b of revenue shows that only a small slice of each sales dollar is turning into profit.
• Bears point out that earnings were negative over the most recent year despite a 5 year average earnings growth rate of 16.8%. The lower 3.6% margin fits that cautious view by highlighting how reimbursement pressure and therapy mix can limit how much revenue growth turns into earnings.
  • Critics highlight that even with trailing revenue of US$5.7b, trailing net income is just over US$200 million, which leaves limited room for error if margins compress further.
  • The bearish narrative also focuses on risks from changing therapy economics, and the step down in margin from 4.1% to 3.6% gives numerical backing to concerns about profitability stability.

Bears worried about margin pressure and therapy mix can see their concerns quantified in these trailing figures, and can go deeper into that cautionary view in the 🐻 Option Care Health Bear Case.

TTM EPS Holds Around US$1.29 Despite Quarterly Swings

• Across the last twelve months, basic EPS is US$1.29, which smooths out the quarterly pattern where Q1 2026 EPS of about US$0.29 sits below the recent Q4 2025 peak of about US$0.37 but close to Q1 2025 at about US$0.28.
• Supporters of the more optimistic narrative see this relatively steady trailing EPS, together with TTM revenue rising from US$5.0b in Q4 2024 to US$5.7b in Q1 2026, as evidence that the business is building a larger base that can absorb some quarterly noise.
  • The bullish view highlights growing utilization in ambulatory infusion clinics and a pipeline of more complex therapies, and the step up in TTM revenue from about US$5.0b to US$5.7b aligns with the idea that the addressable market is expanding.
  • At the same time, the TTM net income line, which moves around the low US$200 million mark over the past six quarters, shows that any bullish case still has to wrestle with relatively thin margins when thinking about long term earnings power.

If you want to see how supporters connect these revenue and EPS trends to a longer term growth story, have a look at the 🐂 Option Care Health Bull Case.

High Debt Meets 15.3x P/E And DCF Gap

• The shares trade on a P/E of 15.3x against trailing EPS of about US$1.29 at a share price of US$20.03, which is below an industry average P/E of 24.9x and below a DCF fair value of about US$25.79, even though the company carries a high level of debt and a trailing net margin of 3.6%.
• Consensus narrative comments that partnerships with payers and pharma, plus investments in clinics and technology, could support revenue growth of around 6.7% and earnings growth of about 11.8% each year. The current valuation gap to both the 30.73 analyst target and DCF fair value sets up a clear tension between growth expectations and the risks from leverage and margin compression.
  • On one hand, the lower 15.3x P/E relative to peers at 58.4x suggests investors are not paying the same multiple as for other healthcare names, even though analysts reference a higher price target of 30.73 compared with the current US$20.03.
  • On the other, the combination of high debt and a net margin that has moved from 4.1% to 3.6% underlines why the market may be reluctant to pay closer to DCF fair value of US$25.79 without clearer signs that profitability can keep pace with the growth forecasts.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Option Care Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both cautious and optimistic views on the table, the real question is where you land once you weigh the trade offs yourself. To better understand how the balance of risks and rewards stacks up before you act, take a closer look at the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Thin 3.6% net margins, recent negative earnings and high debt alongside a 15.3x P/E all point to a business with limited room for error.

If those pressures make you want steadier footing, compare this profile with companies in the 67 resilient stocks with low risk scores that score better on balance sheet strength, earnings quality and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.